Sugi Predict

Sugi Predict / Compounds / SCHEMBL460865

SCHEMBL460865

SCHEMBL460865

Cc1nc2n(c(=O)c1CCCl)CCCC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 9/20 0.49
▸ HTR2A P28223 8/20 0.49
▸ HTR1A P08908 7/20 0.49
▸ KCNH2 Q12809 3/20 0.49
▸ HTR2C P28335 2/20 0.49
▸ ADRA1A P35348 2/20 0.49
▸ HRH1 P35367 2/20 0.49
▸ SMN1; SMN2 Q16637 5/20 0.45
▸ DRD3 P35462 2/20 0.45
▸ SLC22A2 O15244 1/20 0.45
▸ CACNA1F O60840 1/20 0.45
▸ ADRB2 P07550 1/20 0.45
▸ CHRM2 P08172 1/20 0.45
▸ CHRM4 P08173 1/20 0.45
▸ CHRM5 P08912 1/20 0.45
▸ ADRA2A P08913 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ CHRM1 P11229 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ ADRA2B P18089 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1443956 0.98 DRD2 (0.48) DRD2HTR2AHTR1AKCNH2HTR2C
SCHEMBL8338559 0.88 DRD2 (0.49) DRD2HTR2AHTR1AKCNH2HTR2C
SCHEMBL8235846 0.87 DRD2 (0.47) DRD2HTR2AHTR1AKCNH2HTR2C
SCHEMBL5623016 0.87 DRD2 (0.48) DRD2HTR2AHTR1AKCNH2HTR2C
SCHEMBL12345546 0.87 DRD2 (0.48) DRD2HTR2AHTR1AKCNH2HTR2C
SCHEMBL6091966 0.87 DRD2 (0.48) DRD2HTR2AHTR1AKCNH2HTR2C
SCHEMBL9910963 0.87 DRD2 (0.48) DRD2HTR2AHTR1AKCNH2HTR2C
SCHEMBL6493190 0.84 SMN1; SMN2 (0.49) DRD2HTR2AHTR1AKCNH2HTR2C
SCHEMBL11193250 0.83 SMN1; SMN2 (0.51) DRD2HTR2AHTR1AKCNH2HTR2C
SCHEMBL7900687 0.82 MAPK1 (0.41) DRD2HTR2AHTR1AKCNH2HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109705119-B Preparation method of risperidone chloride 浙江华海立诚药业有限公司 2023-05-19 — — CN claimed
US-20100130740-A1 PROCESS FOR PREPARATION OF RISPERIDONE QILU PHARMACEUTICAL CO. LTD. (CN) 2010-05-27 — — US claimed
EP-2035571-A1 ENZYMATIC PROCESS FOR THE PREPARATION OF PALIPERIDONE AND ITS INTERMEDIATE CMHTP Teva Pharmaceutical Industries Ltd. (IL) 2009-03-18 — — EP claimed
US-20090035829-A1 Enzymatic process for the preparation of paliperidone and its intermediate CMHTP INI SANTIAGO 2009-02-05 — — US claimed
WO-2008144073-A1 ENZYMATIC PROCESS FOR THE PREPARATION OF PALIPERIDONE AND ITS INTERMEDIATE CMHTP TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-11-27 — — WO claimed
US-20070293671-A1 Process for the Preparation of Risperidone RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2007-12-20 — — US claimed
EP-1763529-A1 A PROCESS FOR THE PREPARATION OF RISPERIDONE Richter Gedeon Vegy Szeti Gy R Rt. (HU) 2007-03-21 — — EP claimed
WO-2006005974-A1 A PROCESS FOR THE PREPARATION OF RISPERIDONE Richter Gedeon Vegyészeti Gyár Rt. (HU) 2006-01-19 — — WO claimed
US-20060004199-A1 Process for the preparation of pure 3-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one DR. REDDY'S LABORATORIES LIMITED 2006-01-05 — — US claimed
WO-2004009591-A1 A PROCESS FOR THE PREPARATION OF ANTIPSYCHOTIC RISPERIDONE AUROBINDO PHARMA LTD. (IN) 2004-01-29 — — WO claimed
CN-86101906-A Process for preparing 1, 2 benzisoxazol-3-yl and 1, 2 benzisothiazol-3-yl derivatives — 1986-10-01 — — CN claimed
CN-114616229-B Tricyclic compounds and pharmaceutical uses thereof 镇斗生物科技股份公司 2024-09-03 — — CN disclosed
US-20240124456-A1 AZA-ERGOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHANGHAITECH UNIVERSITY (CN) 2024-04-18 — — US disclosed
EP-4286384-A1 AZA-ERGOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ShanghaiTech University (CN) 2023-12-06 — — EP disclosed
CN-109705119-B Preparation method of risperidone chloride 浙江华海立诚药业有限公司 2023-05-19 — — CN disclosed
EP-0505510-A4 ANTIPSYCHOTIC HEXAHYDRO-2-I(H)-INDENO 1,2-C)PYRIDINE DERIVATIVES MCNEILAB INC (US) 1994-08-10 — — EP disclosed
EP-0505510-A1 ANTIPSYCHOTIC HEXAHYDRO-2$i(H)-INDENO 1,2-c]PYRIDINE DERIVATIVES MCNEILAB, INC. (US) 1992-09-30 — — EP disclosed
US-5075315-A Dopamine, serotonin antagonists MCNEILAB, INC. (US) 1991-12-24 — — US disclosed
WO-1991017992-A1 ANTIPSYCHOTIC HEXAHYDRO-2H-INDENO[1,2-c]PYRIDINE DERIVATIVES MCNEILAB INC. (US) 1991-11-28 — — WO disclosed
EP-0453042-A1 Novel 2,9-disubstituted-4H-pyrido-[1,2-a]pyrimidin-4-ones JANSSEN PHARMACEUTICA N.V. (BE) 1991-10-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124456-A1 AZA-ERGOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ERG, CHRNA7, CHRNA5 DRD2 13/4885HTR2A 223/4885HTR1A 129/4885
US-20100130740-A1 PROCESS FOR PREPARATION OF RISPERIDONE CYP3A7, CYP2C19, HTR7 DRD2 141/4885HTR2A 92/4885HTR1A 5/4885
US-20060004199-A1 Process for the preparation of pure 3-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one HTR1A, HTR1B, HTR1D DRD2 59/4885HTR2A 31/4885HTR1A 1/4885
US-20070293671-A1 Process for the Preparation of Risperidone CYP2F1, CYP3A7, CYP2C19 DRD2 35/4885HTR2A 228/4885HTR1A 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.